Levodopa Improves Behavioral Deficits of Mice with Parkinson's Disease Symptoms via Curbing NLRP3 Inflammasome Activation and Enhancing Tyrosine Hydroxylase Levels in the Striatum and Substantia Nigra
Objective: Levodopa (L-DOPA) is the primary treatment for Parkinson’s disease (PD). Nevertheless, the underlying mechanism of its action is not entirely learned. This study aims to probe the action of L-DOPA on NLR pyrin domain containing 3 (NLRP3) inflammasome activation and tyrosine hydroxylase (T...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
IMR Press
2024-01-01
|
Series: | Journal of Integrative Neuroscience |
Subjects: | |
Online Access: | https://www.imrpress.com/journal/JIN/23/1/10.31083/j.jin2301002 |